ResMed Shares Jump Following RBC Capital Upgrade to Outperform
ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.
How this was made
The 30-second read
Why it matters
The upgrade provides a fresh catalyst, likely supporting short‑term buying interest.
Market read
Analyst upgrade with price target increase and a competitor recall creates a near‑term bullish bias for ResMed.
What to watch
Potential regulatory scrutiny on new devices and macro‑economic headwinds could temper growth.
Background
RBC Capital Markets upgraded ResMed (RMD) to Outperform, raising its price target and noting strong growth in sleep‑apnea devices.
Ticker impact
RBC upgraded ResMed to Outperform and raised the price target to $262, prompting a 3% stock rise on the same day.
Potential further upside if the upgrade holds, target around $260.
Upgrade is fresh, includes higher price target, and coincides with a competitor recall, providing a clear catalyst.
Market effects
Positive for the sleep‑apnea device sector as competitor recall may shift demand to ResMed.
U.S. and international markets may see modest gains in medical‑device stocks.
Limited to healthcare equipment niche, not broad market.
Counterpoint
The upgrade may be premature if Philips Respironics returns stronger than expected, pressuring margins.
Key entities
- CompanyResMed
Medical device maker specializing in sleep‑apnea equipment.
- AnalystRBC Capital Markets
Upgraded ResMed and raised price target.
